Evaluation of a standardized short-time calcium suppression test in healthy subjects: Interest for the diagnosis of primary hyperparathyroidism

European Journal of Endocrinology

Volumn 157, Issue 3, 2007, Pages 351-357

  Titon, Isabelle ^a   Cailleux Bounacer, Anne ^a   Basuyau, Jean Pierre ^b   Lefebvre, Hervé ^a,b   Kuhn, Jean Marc ^a,b,c  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE ROUEN   (France)

^c Dept de Médecine Interne Ctr Hosp Univ Rouen Boisguillaume   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; GLUCONATE CALCIUM; PARATHYROID HORMONE;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CALCIUM SUPPRESSION TEST; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; FEMALE; HUMAN; IMMUNOASSAY; LOADING TEST; LUMINESCENCE; MALE; PARATHYROID HORMONE BLOOD LEVEL; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; STANDARDIZATION;

ADULT; AGED; CALCIUM; CALCIUM GLUCONATE; FEMALE; HUMANS; HYPERPARATHYROIDISM, PRIMARY; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHORUS; REPRODUCIBILITY OF RESULTS; SERUM ALBUMIN;

EID: 35348972909     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-07-0132     Document Type: Article

References (52)

1. Bilezikian JP, Brandi ML, Rubin M & Silverberg SJ. Primary hyperparathyroidism: new concepts in clinical densitometric and biochemical features. Journal of Internal Medicine 2005 257 6-17.
2. Bilezikian JP & Silverberg SJ. Asymptomatic primary hyperparathyroidism. New England Journal of Medicine 2004 350 1746-1751.
3. Resnick LM & Laragh JH. Calcium metabolism and parathyroid function in primary hyperparathyroidism. American Journal of Medicine 1985 78 385-390.
4. Silverberg SJ & Bilezikian JP. 'Incipient' primary hyperparathyroidism: a 'forme fruste' of an old disease. Journal of Clinical Endocrinology and Metabolism 2003 88 5348-5352.
5. Hollenberg AN & Arnold A. Hypercalcemia with low-normal serum intact PTH: a novel presentation of primary hyperparathyroidism. American Journal of Medicine 1991 91 547-548.
6. Rao DS, Phillips ER, Divine GW & Talpos GB. Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism 2004 89 5415-5422.
7. Nilsson IL, Yin L, Lundgren E, Rastad J & Ekbom A. Clinical presentation of primary hyperparathyroidism in Europe-nationwide cohort analysis on mortality from nonmalignant causes. Journal of Bone and Mineral Research 2002 17 N68-N74.
8. Nilsson IL, Aberg J, Rastad J & Lind L. Maintained normalization of cardiovascular dysfunction 5 years after parathyroidectomy in primary hyperparathyroidism. Surgery 2005 137 6321-6638.
9. Gogusev J, Duchambon P, Hory B, Giovannini M, Goureau Y, Sarfati E & Drucke TB. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney International 1997 51 328-336.
10. Farnebo F, Enberg U, Grimelius L, Backdahl M, Schalling M, Larsson C & Farnebo LO. Tumor-specific decreased expression of calcium sensing receptor messenger ribonucleic acid in sporadic primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism 1997 82 3481-3486.
11. 2+ set-point in patients with primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism 2000 85 4789-4794.
12. Bergenfelz A, Valdermarsson S & Ahren B. Suppression by calcium of serum levels of intact parathyroid hormone in primary hyperparathyroidism. Hormone Research 1993 39 146-151.
13. Khosla S, Ebeling PR, Firek AF, Burritt MM, Kao PC & Reath H, III. Calcium infusion suggests a set-point abnormality of parathyroid gland function in familial benign hypercalcemia and more complex disturbances in primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism 1993 76 715-720.
14. 2+-sensing function of parathyroid cells in vitro and hyperparathyroidism. Biochimica et Biophysica Acta 1998 968 253-260.
15. Corbetta S, Mantovani G, Lania A, Borgato S, Vicentini L, Beretta E, Faglia G, Di Blasio AM & Spada A. Calcium-sensing receptor expression and signaling in human parathyroid adenomas and primary hyperplasia. Clinical Endocrinology 2000 52 339-348.
16. Yano S, Sugimoto T, Tsukamoto T, Chihara K, Kobayashi A, Kitazawa S, Maeda S & Kitazawa R. Decrease in vitamin D receptor and calcium-sensing receptor in highly proliferative parathyroid adenomas. European Journal of Endocrinology 2003 148 403-411.
17. Broadus AE, Deftos LJ & Bartter FC. Effects of the intravenous administration of calcium on nephrogenous cyclic AMP: use as a parathyroid suppression test. Journal of Clinical Endocrinology and Metabolism 1978 46 477-487.
18. Hagag P, Revet-Zak I, Hod N, Horne T, Rapoport MJ & Weiss M. Diagnosis of normocalcemic hyperparathyroidism by oral calcium loading test. Journal of Endocrinological Investigation 2003 26 327-332.
19. Monchik JM, Lamberton RP & Ruth U. Role of the oral calcium-loading test with measurement of intact parathyroid hormone in the diagnosis of symptomatic subtle primary hyperparathyroidism. Surgery 1992 112 1103-1109.
20. Carmignani G, Belgrano E, Puppo P, Repetto U, Giusti M, Giordano G & Giuliani L. PTH radioimmunoassay and loading tests in the diagnosis of patients with primary hyperparathyroidism. European Urology 1982 8 102-108.
21. Bevilacqua M, Dominguez LJ, Righini V, Valdes V, Vago T, Leopaidi E, Baldi G, Barrella M & Barbagallo M. Dissimilar PTH, gastrin, and calcitonin responses to oral calcium and peptones in hypocalciuric hypercalcemia, primary hyperparathyroidism, and normal subjects: a useful tool for differential diagnosis. Journal of Bone and Mineral Research: 2006 21 406-412.
22. McHenry CR, Rosen IB, Walfish PG & Pollard A. Oral calcium load test: diagnostic and physiologic implications in hyperparathyroidism. Surgery 1990 108 1026-1031.
23. Lepage R, Whittom S, Bertrand S, Bashali G & D'Amour P. Superiority of dynamic over static reference intervals for intact, midmolecule, and C-terminal parathyrin in evaluating calcemic disorders. Clinical Chemistry 1992 38 2129-2135.
24. Howard JE, Hopkins TR & Connor TB. On certain physiologic responses to intravenous administration of calcium salts into normal, hyperrathyroid and hypoparathyroid persons. Journal of Clinical Endocrinology and Metabolism 1953 13 1-19.
25. Khosla S, Melton L III, Wermers RA, Crowson CS, O'Fallon W & Riggs B. Primary hyperparathyroidism and the risk of fracture: a population-based study. Journal of Bone and Mineral Research 1999 14 1700-1704.
26. Vestergaard P, Mollerup CL, Frockjaer VG, Christiansen P, Blichert-Toft M & Mosekilde L. Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ 2000 321 598-602.
27. NIH Conference. Diagnosis and management of asymptomatic primary hyperparathyroidism: consensus development conference statement. Annals of Internal Medicine 1991 114 593-597.
28. Bilezikian JP, Potts JT Jr, Fuleihan Gel H, Kleerekoper M, Neer R, Peacock M, Rastad J, Silverberg SJ, Udelsman R & Wells SA. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. Journal of Clinical Endocrinology and Metabolism 2002 87 5353-5361.
29. Calzada-Nocaudie M, Chanson P, Conte-Devolx B, Delemer B, Estour B, Henry JF, Houillier P, Kraimps JL, Ribot C, Rohmer V, Tabarin A, Verges B, Vidal-Trecan G, Wemeau JL & Weryha G. Management of asymptomatic primary hyperparathyroidism, French Society of Endocrinology consensus. Annales d'Endocrinologie 2006 67 7-12.
30. Brown EM, Broadus AE, Brennan MF, Gardner DG, Marx SJ, Spiegel A, Downs RW Jr, Attie M & Aurbach GD. Direct comparison in vivo and in vitro of suppressibilty of parathyroid function by calcium in primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism 1979 48 604-618.
31. Cirillo M, Strazzullo P, Mattioli PL, Siani A & Cioffi G. Basal parathyroid activity and renal calcium handling during an intravenous calcium load. Nephron 1984 38 167-169.
32. Ramirez JA, Goodman WG, Gornbein J, Menezes C, Moulton L, Segre GV & Salusky IB. Direct in vivo comparison of calcium-regulated parathyroid hormone secretion in normal volunteers and patients with secondary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism 1993 76 1489-1494.
33. Ortolani S, Scotti A & Cherubini R. Rapid suppression of bone resoption and parathyroid hormone secretion by acute oral administration of calcium in healthy adult men. Journal of Endocrinological Investigation 2003 26 353-358.
34. Lips P, Netelenbos JC, van Doorn L, Hackeng WH & Lips CJ. Stimulation and suppression of intact parathyroid hormone (PTH 1-84) in normal subjects and in hyperparathyroid patients. Clinical Endocrinology 1991 35 35-40.
35. McCarron DA, Muther RS, Lenfesty B & Bennett WM. Parathyroid function in persistant hyperparathyroidism: relationship to gland size. Kidney International 1982 22 662-670.
36. Boucher A, D'Amour P, Hamel L, Fugére P, Gascon-Barré M, Lepage R & Ste-Marie LG. Estrogen replacement decreases the set point of parathyroid hormone stimulation by calcium in normal postmenopausal women. Journal of Clinical Endocrinology and Metabolism 1989 68 831-836.
37. Bieglmayer C, Prager G & Niederle B. Kinetic analyses of parathyroid hormone clearance as measured by three rapid immunoassays during parathyroidectomy. Clinical Chemistry 2002 48 1731-1738.
38. Yamashita H, Gao P, Cantor T, Futata T, Murakami T, Uchino S, Wanatabe S, Kawamoto H, Fukagawa M & Noguchi S. Large carboxy-terminal parathyroid hormone (PTH) fragment with a relatively longer half-life than 1-84 PTH is secreted directly from the parathyroid glands in humans. European Journal of Endocrinology 2003 149 301-306.
39. Sherman SS, Holis BW & Tobin JD. Vitamin D status and related parameters in a healthy population: effects of age, sex and season. Journal of Clinical Endocrinology and Metabolism 1990 71 405-413.
40. Eastell R, Yergey AL, Vieira NE, Cedel SL, Kumar R & Riggs BL. Interrelationship among vitamin D metabolism, true calcium absorption, parathyroid function, and age in women: evidence of an age-related intestinal resistance to 1,25-dihydroxyvitamin D action. Journal of Bone and Mineral Research 1991 6 125-132.
41. Quesada JM, Coopmans W Ruiz B, Aljanna P, Jans I & Bouillon R. Influence of vitamin D on parathyroid function in the elderly. Journal of Clinical Endocrinology and Metabolism 1992 75 494-501.
42. Haden ST, Brown EM, Hurwitz S, Scott J & El-Hajj Fuleihan G. The effects of age and gender on parathyroid hormone dynamics. Clinical Endocrinology 2000 52 329-338.
43. Khosla S, Melton LJ III, Atkinson EJ, O'Fallon WM, Klee GG & Riggs BL. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. Journal of Clinical Endocrinology and Metabolism 1998 83 2266-2274.
44. Selby PL & Peacock M. The effects of transdermal oestrogens on bone, calcium-regulating hormones and liver in postmenopausal women. Clinical Endocrinology 1986 25 543-547.
45. Prince RL, Schiff I & Neer RM. Effects of transdermal estrogen replacement on parathyroid hormone secretion. Journal of Clinical Endocrinology and Metabolism 1990 71 1284-1287.
46. Harms HM, Neubauer O, Kayser C, Wustermann PR, Horn R, Brosa U, Schlinke E, Kulpmann WR, von zur Muhlen A & Hesch RD. Pulse amplitude and frequency modulation of parathyroid hormone in early postmenopausal women before and on hormone replacement therapy. Journal of Clinical Endocrinology and Metabolism 1994 78 48-52.
47. Khosla S, Atkinson EJ, Melton LJ III & Riggs BL. Effects of age and estrogen status on serum parathyroid hormone levels and biochemical markers of bone turnover in women: a population-based study. Journal of Clinical Endocrinology and Metabolism 1997 82 1522-1527.
48. Silverberg SJ, Shane E, Dempster DW & Bilezikian JF. The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. American Journal of Medicine 1999 107 561-567.
49. Boudou P, Ibrahim F, Cormier C, Sarfati E & Souberbielle JC. A very high incidence of low 25 hydroxy-vitamin D serum concentration in a French population of patients with primary hyperparathyroidism. Journal of Endocrinological Investigation 2006 29 511-515.
50. Maruani G, Hertig A, Paillard M & Houillier P. Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone. Journal of Clinical Endocrinology and Metabolism 2002 88 4641-4648.
51. Yamauchi M, Sugimoto T, Yamagushi T, Yano S, Kanzawa M, Kobayashi A & Chihara K. Association of polymorphic alleles of the calcium-sensing receptor gene with the clinical severity of primary hyperparathyroidism. Clinical Endocrinology 2001 55 373-379.
52. Cantor T. Parathyroid hormone assay drift: an unappreciated problem in dialysis patient management. Seminars in Dialysis 2005 18 359-364.